Runit announced on the 3rd that it is collaborating with the Society for Immuno-Oncology (SITC), an academic society in the field of immuno-oncology, to provide an AI-based biomarker exploration platform to global researchers.
Lunit and SITC have launched a research support program that provides the AI biomarker solution, 'Lunit SCOPE IO', to SITC members free of charge for a limited period.
Runit Scope IO is an AI solution that has learned massive H&E slide image data. It precisely quantifies the distribution of tumor-infiltrating lymphocytes (TILs), an important indicator for predicting immunotherapy response, and analyzes the tumor microenvironment (TME) to classify it into three immune phenotypes (Immune-activated, Immune-excluded, Immune-desert).
This research support program is open to researchers with a medical doctor (MD) or doctoral degree (PhD) from an academic or non-profit research institution that is a member of SITC, and targets principal investigators with expertise in oncology, pathology, and immunology. Final selection will be made based on the research plan and resume, and the support period is from February 1 to April 30, 2025.
To promote this program, SITC will create a page introducing the Runit Scope IO on its official website and will announce the program in the February and March issues of the 'Immune Monitor' newsletter.
Seo Beom-seok, CEO of Lunit, said, “We are delighted that more global researchers will be able to utilize Lunit’s AI technology through our collaboration with SITC, an authority in the field of immuno-oncology,” and “We will continue to expand our collaboration with global research institutions to lead the change in the medical paradigm based on AI technology.”
“SITC has been working to advance the field of immuno-oncology for the past 40 years,” said Mary Dean, SITC Executive Director. “We hope that this program will further advance the research of SITC members.”
- See more related articles
You must be logged in to post a comment.